Malaria Vaccines for the World

22-24 April 2013, CHUV, Lausanne, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Poster Session

Poster 101
‘Genetic diversity of Plasmodium vivax clinical isolates from Southern Pakistan using pvcsp and pvmsp1 genetic markers’
Afsheen Raza, Najia K. Ghanchi, Ali M. Thaver, Sana Jafri and Mohammad A. Beg (Aga Khan University, Karachi, Pakistan)

Poster 102
‘Assessing community perceptions and acceptability of malaria vaccines: A sociological investigation of the urban community’
Frederick A.D. Kaona and Esnart Miti (MSHRI, Ndola, Zambia)

Poster 103
‘Urban malaria and associated risk factors in Jimma town, south-west Ethiopia’
Abebe Alemu, Wondewosan Tsegaye, Lemu Golassa and Gemeda Abebe (Jimma University, Jimma, Ethiopia)

Poster 104
‘Impact of Plasmodium falciparum infection on haematological parameters in children less than fifteen years of age with abnormal haemoglobulin living in a malaria endemic area of Burkina Faso’
E. Bougouma et al. (CNRFP, Ouagadougou, Burkina Faso)

Poster 105
‘HLA-DR4 molecules suppress antibody responses to malaria blood stage parasites’
Rebecca Danner, Wathsala Wijayalath, Yuliya Kleschenko, Thomas L. Richie, Eileeen Villasante, Chella David, Teodor-Doru Brumeanu and Sofia Casares (Naval Medical Research, Silver Spring, Maryland, USA)

Poster 106
‘Optimization of the Plasmodium knowlesi-Rhesus monkey challenge model for pre-clinical screening of malaria vaccine candidates’
David Fryauff, Walter Weiss, Jittawadee Murphy, Thomas L. Richie, Michael Fay, Gyan Joshi, Kevin Lee, Paul Howell, Robert Gwadz, Megan Dowler, Alejandra Zapata, Jason Richardson and Jingyang Chen (Naval Medical Research, Silver Spring, Maryland, USA)

Poster 107
‘Development of a vaccine that blocks erythrocyte invasion of Plasmodium falciparum
Julie Healer et al. (Walter & Eliza Hall Institute for Medical Research, Parkville, Victoria, Australia)

Poster 108
‘Maintenance of antibody and cytokine responses against Plasmodium falciparum in immigrants after extended periods of interrupted exposure to malaria’
Gemma Moncunill et al. (CRESIB, Barcelona, Spain)

Poster 109
‘Safety and immunogenicity results from the first ‘mixed modality’ clinical trial combining viral vectored and protein-in-adjuvant vaccines targeting the blood-stage antigen Plasmodium falciparum AMA1’
Susanne H. Sheehy et al. (The Jenner Institute, University of Oxford, Oxford, UK)

Poster 110
‘Heterologous protection against malaria in a subset of volunteers after immunizations with Plasmodium falciparum sporozoites under chloroquine prophylaxis’
Remko Shats et al. (Leiden University Medical Centre, Leiden, The Netherlands)

Poster 111
‘Cellular immune correlates of protection in human volunteers immunized with Plasmodium falciparum sporozoites’
Else M. Bijker et al. (Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands)

Poster 112
‘Comparison of two plasmodium DNA extraction methods from thick blood films’
Mvumbi Makaba D. (University of Kinshasa, Kinshasa, DRC)

Poster 113
‘Mechanistic basis of Plasmodium falciparum neutralization by antibodies against PfRH5’
Alexander D. Douglas et al. (The Jenner Institute, University of Oxford, Oxford, UK)

Poster 114
‘Evaluation of a protective immune response via Antibody-Dependent Respiratory Burst (ADRB)-assay’
Stephanie Kapelski et al. (RWTH Aachen/Fraunhofer IME, Aachen, Germany)

Poster 115
‘Lessons learned in coordinating a multiple partner consortium undertaking a malaria vaccine trial’
Brenda Okech (Statens Serum Institute, Copenhagen, Denmark)

Poster 116
‘Isolation of Plasmodium falciparum specific human monoclonal antibodies by Mini Phage display’
Melanie Seidel et al. (RWTH/Aachen/Fraunhofer, Aachen, Germany)

 

MVW 2013 Delegates

Login details will be supplied after you have registered for the event.


MVW 2013 Sponsors

  • Nature Gene Therapy
  • EVI
  • DNA Vaccine
  • Sanaria
  • MVI PATH
  • Aldevron
  • Malaria No More
  • Malaria World

MVW 2013 Downloads

MVW 2013 Leaflet

MVW 2013 Mailing List

Name
E-mail Address
What is 1+4-2?